Abstract: The subject invention pertains to agonist peptides of type I interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the C-terminus region of the type I IFN molecules and are capable of binding to the cytoplasmic domain of type I IFN receptors. Surprisingly, these peptides were found to possess the same or similar biological activity as that associated with the full-length, mature type I IFN proteins, even though these peptides do not bind to the extracellular domain of the type I IFN receptors. In one embodiment, the peptide is a peptide of IFN?. In another embodiment, the peptide is a peptide of IFN?. Exemplified peptides of the invention include those having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. The subject peptides have been shown to effect increased resistance to viral infection.

Abstract: The invention relates to truncated BMP-4 growth factors and variants thereof. The invention also relates to methods of making and using the truncated BMP-4 growth factors.

Abstract: The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Abstract: The embodiments provide a calcitonin gene-related peptide (CGRP) agonist peptide or pharmaceutically acceptable salt thereof, including pharmaceutical compositions comprising a CGRP agonist peptide. The embodiments further provide treatment methods, including method of treating metabolic disorders and metabolic disorders selected from metabolic syndrome, diabetes and obesity. The methods involve administering to a subject in need thereof an effective amount of CGRP peptide.

Abstract: The present invention provides peptide analogs of ?-MSH and ?-MSH, comprising the amino acid sequence of human ?-MSH or ?-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.

Abstract: This document provides methods and materials related to vesicular stomatitis viruses. For example, vesicular stomatitis viruses, nucleic acid molecules encoding VSV polypeptides, methods for making vesicular stomatitis viruses, and methods for using vesicular stomatitis viruses to treat cancer are provided.

Abstract: The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling HIV replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the HIV-specific CTL response to allow long-term viral suppression or viral clearance. Human hematopoietic stem cells (HSCs) were genetically modified such that they differentiate into mature CTLs that will kill HIV infected cells. As disclosed herein, the functional effector cells are not human leukocyte antigen (HLA)-restricted. As disclosed herein, stem cells are transduced with non-HLA restricted chimeric antigen receptors (CARs) that allow the recognition of HIV or HIV-infected cells when expressed by a CTL. These CARs are hybrid molecules that contain an extracellular HIV recognition domain and an intracellular TCR-zeta signaling domain. The CTL response may be enhanced through the targeting of T cell inhibitory receptors.

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.

Abstract: Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed, wherein the methods and compositions of the invention are based on the use of non-glycosylated apolipoprotein A-IV produced by a protein expression system, such as a bacterial expression system. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof based on administering non-glycosylated apolipoprotein A-IV produced by a protein expression system.

Abstract: Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries. Further disclosed are methods for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and methods for producing a disulfide-stabilized single chain antibody and non-fusion form thereof.

Abstract: The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.

Abstract: The purpose of the present invention is to provide a substance having superior antibacterial activity against Pseudomonas aeruginosa, and a pharmaceutical composition for treatment and/or prophylaxis of pseudomonal infections. A pharmaceutical composition is provided, containing an antibody which specifically binds to the LPS O11 antigen of Pseudomonas aeruginosa, and which has superior antibacterial activity.

Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.

Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.

Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.

Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.

Abstract: The present disclosure describes novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further describes use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.

Abstract: Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.

Abstract: Interleukin 6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.

Abstract: The present invention provides antibodies that bind to prokineticin receptors (PROKRs) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PROKR1 and/or PROKR2. The present invention includes antibodies that bind cell surface-expressed PROKR1 and/or PROKR2. In certain embodiments, the antibodies of the present invention are capable of blocking prokineticin (PK)-mediated activation of one or more PROKR. The antibodies of the invention are useful for the treatment of various diseases and disorders mediated by prokineticin signaling.

Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.

Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies, comprising the same, and their uses.

Abstract: The invention relates to the production and the characterization of new murine monoclonal antibodies that recognize the domain CTDL-2 (SEQ ID NO: 1) of the cell receptor DEC-205 of dendritic cells in chickens (Gallus gallus), pigs, (Sus scrofa) and humans (Homo sapiens). The invention also relates to the capacity of the new antibodies to direct and modulate the immune response at different levels in chickens (Gallus gallus) and pigs (Sus scrofa), as well as recognizing the receptor DEC-205 in dentritic cells and cell lines in humans. In addition, the invention is used to quickly produce a specific humoral immune response against Hemaglutinina H5 of the H5N2-type avian flu virus.

Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions.

Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present disclosure relates to conjugates comprising biologically active molecules linked to a multimeric antigen-binding compound or a multimeric immunoglobulin via a linker. The disclosure further provides reagents and methods of manufacturing the conjugates and the linkers. The disclosure also provides compositions comprising the conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.

Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.

Abstract: Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating Globo-H-positive cancer.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.

Abstract: Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.

Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.

Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160° C.

Abstract: The invention relates to a method for production of a preparation from a vegetable material, said preparation being enriched in a polysaccharide with a backbone comprising rhamnogalacturonan-I cores, said method comprising the steps: mixing the vegetable material with a polar alcoholic solvent; and separating a solid residue obtained in step a) from the solvent; and mixing the solid residue obtained in step b) with a buffered aqueous solution having a pH between 7 and 8. Also provided is a preparation containing rhamnogalacturonan-I pectins that can be obtained by this method and the use of such a preparation to modulate immune response.

Abstract: Methods and systems for synthesizing heparin compounds are provided. The chemoenzymatic synthesis of structurally homogeneous low molecular weight heparins that have a reversible anticoagulant activity is provided. Also disclosed are heparin compounds having anticoagulant activity, including a binding affinity to antithrombin and an anti-Xa activity, but no detectable anti-lla activity. Additionally, provided are synthetic, low-molecular weight heparin compounds with reversible anticoagulant activity, where the anticoagulant activity is reversible by protamine.

Abstract: Disclosed are an end-modified conjugated diene-based polymer configured such that the end of a conjugated diene-based polymer is coupled with an aminosilane-based end modifier, and a method of preparing the same.

Abstract: A method of producing a polymer latex drag reducer. The method begins by forming an aqueous solution comprising a surfactant, a buffer and water. The method then forms an organic solution comprising a monomer and a co-stabilizer. The aqueous solution and the organic solution are mixed to form an emulsion. The emulsion is then subjecting to a high shear device to produce a miniemulsion, wherein the monomers are broken into small droplets followed by polymerizing the miniemulsion with the addition of an initiator, wherein a nucleation occurs in the small monomer droplets.

Abstract: Heterocyclic organic compounds are used as electron donors in conjunction with solid Ziegler-Natta type catalyst in processes in which polyolefins such as polypropylene are produced. The electron donors may be used in the preparation of solid catalyst system, thus serving as “internal electron donors”, or they may be employed during or prior to polymerization with the co-catalyst as “external electron donors”.

Abstract: A method for preparing ammonium tetrakis(pentafluorophenyl)borate salt comprising reacting a secondary amine with an aldehyde to form an iminium ion; hydrogenating the iminium ion by reaction with a reducing agent to form a tertiary amine; reacting the tertiary amine with a mineral acid to form an amine salt; and reacting the amine salt with K[B(C6F5)4], Li[B(C6F5)4], or combinations thereof to form an ammonium tetrakis(pentafluorophenyl)borate salt, wherein the secondary amine is derived from a non-animal source and the aldehyde has seven or more carbon atoms; wherein the ammonium tetrakis(pentafluorophenyl)borate salt is characterized by a solubility at 25° C. in hexane, cyclohexane or methylcyclohexane of at least 10 weight percent; and wherein the tertiary amine has a molecular weight of at least 450 g/mole is provided.

Abstract: A polyvinyl acetal resin for a heat-developable photosensitive material capable of preventing skinning in the coating process of the photosensitive layer of the heat-developable photosensitive material, preventing deterioration of image characteristics and coloration of the coating solution, and suppressing the occurrence of odor at the time of producing the heat-developable photosensitive material and heat development. The polyvinyl acetal resin for a heat-developable photosensitive material used for a photosensitive layer of the heat-developable photosensitive material has a residual acetyl group content of 25 mol % or less, residual hydroxyl group content of 17-35 mol %, and polymerization degree of 200 to 3,000, and is obtained by an acetalization of a polyvinyl alcohol mixture containing polyvinyl alcohol resins having different polymerization degrees, wherein the content of the polyvinyl alcohol having a polymerization degree of 600 or less is 50 wt % or higher in the polyvinyl alcohol mixture.

Abstract: This invention relates to a process to produce propylene polymer using a bridged hafnium transition metal metallocene catalyst compounds having two indenyl ligands substituted at the 4 positions with a C1 to C10 alkyl, where the 3 positions are hydrogen (assuming the bridge position is counted as the one position) and the bridging atom is carbon or silicon which is incorporated into a cyclic group comprising 3, 4, 5, or 6 silicon and/or carbon atoms that make up the cyclic ring, where the propylene polymer has 1) greater than 40% vinyl chain ends, relative to the total unsaturated chain ends, 2) a Tm of 70° C. or more; an Mw of 3000 to 300,000 g/mol, and 4) a g?vis of 0.90 or less.

Abstract: Catalyst compositions containing activator-supports and half-metallocene titanium phosphinimide complexes or half-metallocene titanium iminoimidazolidide complexes are disclosed. These catalyst compositions can be used to produce olefin polymers having relatively broad molecular weight distributions and low levels of long chain branching.

Abstract: Spherical carriers for an olefin polymerization catalyst, catalyst components, catalysts, and preparation methods therefor are disclosed. The method for preparing the spherical carriers comprises the following steps: (1) reacting, in the presence of at least one polymeric dispersion stabilizer, a magnesium halide with an organic compound containing active hydrogen to form a complex solution; (2) reacting said complex solution with an alkylene oxide-type compound to directly precipitate solid particles; and (3) recovering the solid particles to obtain spherical carriers. When a catalyst prepared by using the present spherical carrier is used in propylene polymerization, said catalyst exhibits high polymerization activity and high stereo-directing ability.

Abstract: Disclosed herein are dual catalyst compositions containing an unbridged metallocene compound, a bridged metallocene compound, a chemically-treated solid oxide, and an optional co-catalyst. These catalyst compositions can be used for the oligomerization of propylene to produce an oligomer product. For example, a heavy propylene oligomer can be recovered from the oligomer product, and the heavy propylene oligomer can be characterized by a high flash point and viscosity index, and a low pour point.

Abstract: A compound represented by formula (I), a resin including a structural unit derived from the compound and a resist composition including the resin: wherein R1 represents a hydrogen atom, a halogen atom or a C1 to C6 alkyl group in which a hydrogen atom may be replaced by a halogen atom, R2 represents a C1 to C6 perfluoroalkyl group or *—CHRf1Rf2, * represents a binding site to a carbonyl group, Rf1 and Rf2 each independently represent a C1 to C4 perfluoroalkyl group or Rf1 and Rf2 may be bonded together with a carbon atom bonded thereto to form a ring, A1 represents a single bond, a C1 to C6 alkanediyl group or **-A3-X1-(A4-X2)a-(A5)b-, ** represents a binding site to an oxygen atom, A2, A3, A4 and A5 each independently represent a C1 to C6 alkanediyl group, X1 and X2 each independently represent —O—, —CO—O— or —O—CO—, a and b each represent 0 or 1, and W1 represents a C5 to C18 divalent alicyclic hydrocarbon group.

Abstract: A process is provided for preparing a coupled polymer by anionic polymerization wherein the coupled polymer is a conjugated diene polymer comprising the following reaction steps: a) polymerizing a monomer or a mixture of monomers comprising at least one conjugated diene optionally one or more monoalkenyl arene compounds in the presence of an anionic initiator to form a living polymer arm or mixture of arms with an average apparent molecular weight greater than 2000; b) reacting the living polymer arm or arms with a polyalkenyl coupling agent; c) terminating the polymerization if any living polymers remain after step b); and d) optionally functionalizing and/or hydrogenating the coupled polymer so produced, wherein the polyalkenyl coupling agent is an alpha,omega-bis(vinylphenyl)alkane. Also provided is the polymer so prepared and its use in concentrates, aqueous emulsions and products made from aqueous emulsions.